[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiotherapy-conformal-imrt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiotherapy-conformal-imrt":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100648696","sgrt-in-head-and-neck-cancer-radiotherapy-100648696",false,"NCT07726407","SGRT in Head and Neck Cancer Radiotherapy","A Prospective, Phase II, Randomized Controlled Study of Surface Guided Radiation Therapy (SGRT) in Head and Neck Cancer Radiotherapy","Inclusion Criteria:\n\n* Age ≥ 18 years, \\\u003C75 years.\n* Histologically or cytologically confirmed head and neck malignant tumors （including nasopharynx, oropharynx, larynx, hypopharynx, oral cavity, etc.）.\n\nStage T1-4, N0-3, M0 （Stage I-IVa） according to AJCC 8th edition.\n\n* Planned to receive radical radiotherapy （with or without concurrent chemotherapy\u002F targeted therapy）.\n* Ability to tolerate breath-hold ≥ 30 seconds and to complete necessary couch shifts for patient positioning during a single breath-hold.\n\nExclusion Criteria:\n\n* Prior head and neck radiotherapy.\n* Brain tumor radiotherapy.\n* Non-conventional fractionation radiotherapy (e.g., hypofractionation, hyperfractionation, SBRT) is planned.\n* Pregnant or lactating women.","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is a prospective, randomized, open-label, single-center exploratory trial. A total of 40 newly diagnosed, untreated head and neck cancer patients （stage I-IVa, AJCC 8th edition） will be enrolled and randomly assigned in a 1：1 ratio to either the experimental group or the control group. The experimental group will receive radiotherapy immobilization using optical surface guidance technology combined with an open-face mask, while the control group will undergo conventional positioning with a closed head-neck-shoulder thermoplastic mask. The primary objective is to compare the six-dimensional setup errors derived from cone-beam CT （CBCT） registration and intrafraction motion between the two groups. The secondary objective is to compare dosimetric parameters of organs at risk （including lens, eyeball, spinal cord, brainstem, temporal lobe, parotid gland, submandibular gland, thyroid gland, mandible, and temporomandibular joint） between the two groups. The safety of the optical surface-guided open-face mask technique will be evaluated by monitoring radiotherapy-related adverse effects during and after treatment. This study aims to investigate whether optical surface guidance combined with open-face immobilization can improve patient comfort, provide more precise radiotherapy, and enhance the protection of normal tissues.",[27,28],"Head and Neck Cancer","Radiotherapy, Conformal (IMRT)",[30,31,32],"head and neck cancer","optical surface guidance technology","radiotherapy","RECRUITING","2026-07-22",{"date":36,"type":37},"2026-07-24","ACTUAL",{"date":39,"type":37},"2026-06-15",{"date":41,"type":21},"2028-12-30",{"name":43,"class":44},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100580023","radiotherapy-of-head-and-neck-cancer-with-sib-100580023","NCT06831903","Radiotherapy of Head and Neck Cancer With SIB","Simultaneous Integrated Boost in the Primary and Adjuvant Therapy of Head and Neck Cancer: Quality Control Registry Prospective Longitudinal Obervation Trial","Inclusion Criteria:\n\n* Patients aged 18 and older with histologically confirmed malignant head and neck tumors, undergoing definitive or adjuvant radio(chemo)therapy at the University Hospital Würzburg\n\nExclusion Criteria:\n\n* missing informed consent\n* mental or physical disorders leading to inability to understand and\u002For fill the quationary\n* judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures",{"count":54,"type":21},750,"5 Years","OBSERVATIONAL","Title: Simultaneous Integrated Boost in Primary and Adjuvant Therapy of Head and Neck Tumors: Quality Control Registry Prospective Longitudinal Observational Study\n\nShort Title: Radiotherapy for Head and Neck Tumors with SIB\n\nObjective: To evaluate the efficacy and safety of definitive and adjuvant radio(chemo)therapy with simultaneous integrated boost (SIB) in patients with head and neck cancers. The study aims to assess local and regional control, overall survival, metastasis-free survival, therapy-related toxicities, and quality of life.\n\nStudy Design: A prospective, longitudinal, non-interventional registry study documenting real-world outcomes and quality measures of therapy applied according to existing clinical guidelines.",[59,27,60,28],"Quality of Life (QOL)","Radiotherapy Side Effect","2025-02-12",{"date":63,"type":37},"2025-02-18",{"date":65,"type":37},"2019-05-21",{"date":67,"type":21},"2039-10-01",{"name":69,"class":44},"Wuerzburg University Hospital"]